Switching Between Foundayo (Orforglipron) and Zepbound (Tirzepatide): What the FDA Labels Say About Dose Equivalence (2026)

Foundayo (orforglipron) and Zepbound (tirzepatide) are different molecules with different routes (oral pill vs subcutaneous injection), different dosing intervals (daily vs weekly), different dose strengths, and different published efficacy ceilings. The FDA labels for both drugs do NOT contain a dose-equivalence conversion table. There is no FDA-approved “X mg of Foundayo equals Y mg of Zepbound” lookup. There is also no published head-to-head trial comparing them as of mid-2026. This article walks through the verbatim §2 dose ranges of both DailyMed labels, the cross-trial efficacy comparison (ATTAIN-1 17.2 mg = −11.1% body weight at 72 weeks vs SURMOUNT-1 15 mg = −20.9% at 72 weeks — separate trials, separate populations), the practical re-titration logic published in §2 of each label, and the pregnancy / insurance considerations that often drive switching. The article does NOT recommend a specific switch protocol — switching between these two drugs is a prescriber decision.

Why patients ask about switching

The questions our editors hear most often after Foundayo's approval in April 2026 cluster into a small set of recurring scenarios. None of them are pure “Foundayo is better, I want to switch” — every one is anchored to a real constraint:

• Insurance formulary swap. CVS Caremark announced in July 2025 that as of July 2026 only Wegovy would be on its standard commercial formulary for chronic weight management; Zepbound was excluded. Patients on Zepbound through a Caremark plan have asked whether Foundayo (oral, no fridge, $149/month at LillyDirect / Amazon Pharmacy cash-pay) is a viable backstop if their plan refuses to cover Wegovy or denies them. See our insurance dropped coverage appeal playbook for the prior-auth re-application path after a plan change.
• GI tolerability on Zepbound. Zepbound's §6 ADVERSE REACTIONS table reports nausea up to 33%, diarrhea up to 22%, vomiting up to 13%, and constipation up to 17% at various doses. Some patients reach a tolerability ceiling that does not improve with dose-spacing or anti-emetics and ask whether oral orforglipron at a lower dose level might be better tolerated. The honest answer: there is no published trial data comparing GI tolerance between the two drugs in the same patients.
• Oral vs injection preference. Some patients dislike weekly subcutaneous injections — needle anxiety, lost / damaged pens, refrigeration and travel logistics, or simply a preference for a daily pill. Foundayo's once-daily tablet, no fridge, no needles, no injection-site reactions is a meaningful lifestyle change.
• Dose availability / supply. Tirzepatide was on the FDA shortage list from late 2022 through October 2024. Although the shortage has resolved, patients who experienced intermittent pen availability ask whether oral Foundayo is a more reliable supply chain.
• Plateau on top-dose Zepbound. A small fraction of patients reach 15 mg Zepbound and continue to plateau without further weight loss for many months. They ask whether switching to Foundayo represents a different mechanism that might restart loss. There is no published trial evidence supporting this hypothesis — orforglipron and tirzepatide both act on the GLP-1 receptor (tirzepatide also acts on GIP), and a plateau is more likely to reflect underlying body-composition adaptation than receptor tachyphylaxis.
• Cost. Foundayo cash-pay through Lilly Direct / Amazon Pharmacy is approximately $149/month for any strength as of 2026. Zepbound's LillyDirect self-pay single-vial program is approximately $349/month at 5 mg / $499 at 7.5 mg / $499 at 10 mg / $599 at 12.5 mg / $699 at 15 mg. For a patient losing brand-name pen coverage, cash-pay Foundayo is roughly the cost of the lowest Zepbound dose.

These scenarios are the “why.” The mechanics of switching — whether and how to re-titrate, what the labels actually allow, what dose to start on — are not addressed by either FDA label as a switch protocol. There is no §2 “Switching from Zepbound to Foundayo” subsection in either prescribing information.

What the FDA labels actually say (verbatim §2)

Before any switching discussion, the dose ranges of each drug as written in the FDA labels:

Foundayo (orforglipron) §2

“Take FOUNDAYO orally once daily, with or without food. Swallow tablets whole. Do not break, crush, or chew. The starting dosage is 0.8 mg orally once daily. After at least 30 days on the 0.8 mg dosage, increase the dosage to 2.5 mg once daily. After at least 30 days on the 2.5 mg dosage, increase the dosage to 5.5 mg once daily. The dosage may be increased to the next dosage level (9 mg, 14.5 mg, or 17.2 mg once daily) after at least 30 days on the current dosage, based on treatment response and tolerability. The maximum dosage of FOUNDAYO is 17.2 mg once daily.”

Foundayo's six FDA-approved strengths are 0.8, 2.5, 5.5, 9, 14.5, and 17.2 mg, taken as a single tablet once daily, with at least 30 days between any two escalations.

Zepbound (tirzepatide) §2

“The recommended starting dosage of ZEPBOUND for all indications is 2.5 mg injected subcutaneously once weekly for 4 weeks. After 4 weeks, increase the dosage to 5 mg injected subcutaneously once weekly. The dosage may be increased in 2.5 mg increments, after at least 4 weeks on the current dose. The recommended maintenance dosage is 5 mg, 10 mg, or 15 mg, injected subcutaneously once weekly. The maximum dosage of ZEPBOUND for all indications is 15 mg injected subcutaneously once weekly.”

Zepbound's six FDA-approved strengths are 2.5, 5, 7.5, 10, 12.5, and 15 mg, injected subcutaneously once weekly, with at least 4 weeks between any two escalations. Note that 7.5 mg and 12.5 mg are intermediate titration steps; 5, 10, and 15 mg are the three labeled maintenance doses.

Side-by-side dose-range comparison

This is the closest thing to an “equivalence” table the FDA labels support — a side-by-side of the structural attributes of each drug. It is not a conversion lookup. There is no row that says “Foundayo X mg = Zepbound Y mg.”

Foundayo's §1 indication verbatim: “FOUNDAYO is indicated in combination with a reduced-calorie diet and increased physical activity to reduce excess body weight and maintain weight reduction long term in adults with obesity or adults with overweight in the presence of at least one weight-related comorbid condition.” Zepbound's §1 indication verbatim: “ZEPBOUND® is indicated in combination with a reduced-calorie diet and increased physical activity: to reduce excess body weight and maintain weight reduction long term in adults with obesity or adults with overweight in the presence of at least one weight-related comorbid condition. to treat moderate to severe obstructive sleep apnea (OSA) in adults with obesity.” Zepbound is the only one of the two drugs FDA-approved for OSA in adults with obesity.

What the labels do NOT say

Both the Foundayo and Zepbound DailyMed labels were checked on 2026-05-09. Neither label contains:

• A dose-equivalence table mapping Foundayo strengths to Zepbound strengths (or vice versa).
• A §2 subsection titled “Switching from tirzepatide” or “Switching from orforglipron.”
• Any statement that “X mg of orforglipron is equivalent to Y mg of tirzepatide” in efficacy, exposure, or receptor occupancy.
• Any cross-reference between the two prescribing informations on any topic other than the class-wide GLP-1 boxed warning for thyroid C-cell tumors.

The reason is structural. The two drugs were developed by different programs, approved on the basis of different phase 3 trials (ATTAIN program for orforglipron; SURMOUNT program for tirzepatide), and have different mechanisms of action. There is no shared pharmacokinetic anchor that would let the FDA publish a 1:1 conversion. Any equivalence claim circulating online — “5.5 mg Foundayo is like 2.5 mg Zepbound,” “17.2 mg Foundayo is like 7.5 mg Zepbound” — is not from either FDA label and is not from a peer-reviewed primary source. We do not endorse such claims and patients should not rely on them.

Cross-trial efficacy comparison (with caveats)

The published phase 3 evidence at the maximum approved dose of each drug, in the obesity / overweight indication, at 72 weeks:

Critical caveat: this is a cross-trial comparison, not a head-to-head. ATTAIN-1 and SURMOUNT-1 enrolled different patient populations, used different inclusion criteria, ran in different calendar years, and had different run-in protocols. The published difference in mean weight loss does not necessarily reflect what either drug would produce in the same patient. As of mid-2026 there is no head-to-head randomized trial comparing Foundayo to Zepbound. SURMOUNT-5 (PMID 40353578, NEJM 2025) compared tirzepatide to semaglutide head-to-head, not tirzepatide to orforglipron.

Within-trial dose-response also differs:

• ATTAIN-1 (Foundayo, 72 wks): 5.5 mg −7.4%, 9 mg −8.3%, 17.2 mg −11.1%, placebo −2.1%.
• ATTAIN-2 (Foundayo + T2D, 72 wks): 5.5 mg −5.1%, 9 mg −7.0%, 17.2 mg −9.6%, placebo −2.5%.
• SURMOUNT-1 (Zepbound, 72 wks): 5 mg −15.0%, 10 mg −19.5%, 15 mg −20.9%, placebo −3.1%.

Two clinical observations follow that are honest readings of the published data, not switch protocols:

• The Zepbound 5 mg maintenance dose produced approximately −15% body weight at 72 weeks in SURMOUNT-1. The Foundayo top dose 17.2 mg produced approximately −11% body weight at 72 weeks in ATTAIN-1. In simple cross-trial mean-weight-loss terms, Zepbound at its lowest maintenance dose out-performed Foundayo at its highest dose. This does not predict an individual patient's response — dose-response variance within either trial is substantial — but it does inform the prescriber-patient conversation about expected ceiling of response.
• Patients switching from Zepbound 15 mg to Foundayo 17.2 mg should not expect equivalent mean weight loss based on published data alone. Whether to switch is a decision that may rest on factors other than peak weight loss — cost, access, route preference, GI tolerability, family planning (see below).

Practical re-titration logic when switching

Because neither label addresses switching from one drug to the other, the most defensible framework is to treat any switch as functionally equivalent to a long missed-dose interval and apply each drug's own missed-dose rule from §2.

Foundayo §2 missed-dose rule (verbatim)

“If a dose is missed, instruct patients to take the dose as soon as possible. If 7 or more consecutive doses are missed, reinitiate dosage escalation at a lower dosage to reduce the risk of gastrointestinal adverse reactions.”

Translation when applied to a switch onto Foundayo from Zepbound: a patient who has been off any GLP-1 for ≥7 days should expect to start at a low Foundayo dose — typically the 0.8 mg starting dose, or at the prescriber's discretion the 2.5 mg first step-up — rather than attempting to begin at a high dose to “match” their prior Zepbound exposure. The practical reason: GI tolerance fades within days of stopping a GLP-1, so the GI hit of starting at a high dose is real even for patients with high prior exposure.

Zepbound “more than 4 days” rule (Zepbound §2)

Zepbound's §2 specifies that a missed dose can be taken within 4 days of the missed day; if more than 4 days have passed, skip the missed dose and resume on the next regular weekly day. Zepbound does not have an explicit Foundayo-style “7+ missed doses → re-titrate” sentence, but clinical practice for any tirzepatide gap longer than ~4-6 weeks is conservative re-titration starting at a lower step. Switching onto Zepbound from Foundayo is therefore most defensibly handled by starting at the 2.5 mg starter dose and following the standard ≥4-week-per-step ladder, not by attempting to skip directly to a high maintenance dose.

The implicit washout window between drugs

Tirzepatide's elimination half-life is approximately 5 days, so a patient's last Zepbound dose continues to exert receptor effects for roughly 3-4 weeks after the injection. Orforglipron is a small molecule with a much shorter elimination half-life (approximately 24-29 hours per Lilly's phase 1 data); a patient's last Foundayo dose largely clears within 5-7 days. The practical implication is asymmetric:

• When switching from Zepbound to Foundayo, there is residual tirzepatide for several weeks after the last injection. Starting Foundayo immediately after the next missed weekly Zepbound day means stacking GLP-1 effects in the early days; some prescribers prefer a 1-2 week pause before initiating Foundayo to let tirzepatide clear partly.
• When switching from Foundayo to Zepbound, most orforglipron clears within a week of the last tablet, so the practical washout is shorter. The first Zepbound injection enters a substrate that is largely free of prior GLP-1 effect.

These are pharmacokinetic observations, not switch protocols. The decisions of when to time the switch, what dose to start on, and how fast to escalate are prescriber-level decisions anchored to the individual patient. For the broader GLP-1 switching landscape see our switching between GLP-1 medications guide and the missed-dose decision guide. For the analogous switch between the two injectable weight-loss GLP-1s — Wegovy (semaglutide 2.4 mg) ↔ Zepbound (tirzepatide 15 mg), the switch driven hardest by the CVS Caremark July 2025 formulary swap and anchored to the SURMOUNT-5 head-to-head trial (PMID 40353578) — see our Wegovy ↔ Zepbound switch dose-equivalence guide.

Pregnancy and birth-control considerations

Both Foundayo and Zepbound carry pregnancy-related precautions that matter for any switch decision involving a patient who could become pregnant.

Foundayo §8.1, §8.3

Foundayo's §8.1 states that there are limited human data on use during pregnancy; in animal reproduction studies, orforglipron caused embryofetal toxicity at exposures relevant to humans. The label recommends discontinuation of Foundayo when pregnancy is recognized. §8.3 (females and males of reproductive potential) advises discontinuation of Foundayo at least 6 weeks before a planned pregnancy, due to the approximately 24-29 hour half-life and the time needed to clear before conception. Foundayo does not carry a Zepbound-style oral-contraceptive bioavailability footnote.

Zepbound §8.1, §8.3, §7

Zepbound's §8.1 includes the same animal-data embryofetal-toxicity language and a similar recommend-discontinuation-on-recognized-pregnancy stance. §8.3 advises Zepbound discontinuation at least 2 months before a planned pregnancy due to tirzepatide's longer ~5-day elimination half-life. Critically, Zepbound §7 contains the oral-contraceptive bioavailability footnote that Foundayo does not: tirzepatide delays gastric emptying and may reduce the bioavailability of oral combined hormonal contraceptives. The label advises that patients on oral contraceptives switch to a non-oral method, or add a barrier method, for 4 weeks after initiating Zepbound and 4 weeks after each dose escalation. See our Mounjaro / Zepbound birth-control warning evidence article for the full citation.

Implications for switching

A patient switching from Zepbound to Foundayo who is on oral contraceptives loses the Zepbound bioavailability concern (the Foundayo label does not contain an equivalent footnote). A patient switching from Foundayo to Zepbound who is on oral contraceptives gains the bioavailability concern and must address it with their prescriber at the time of the switch and at each Zepbound escalation. This is not captured in any equivalence table — it is a label-asymmetry that only emerges from reading both prescribing informations.

Insurance and formulary considerations

Switching is increasingly driven by formulary changes rather than clinical preference. The two largest 2025-26 examples:

• CVS Caremark (July 2025 announcement, July 2026 effective): Caremark's standard commercial formulary preferred Wegovy for chronic weight management; Zepbound was excluded. Patients on Zepbound through Caremark plans were instructed to switch to Wegovy (semaglutide), not Foundayo. But because Foundayo is the lowest-cost FDA-approved chronic-weight-management GLP-1 on cash-pay ($149/month at LillyDirect / Amazon Pharmacy), it has become a backstop option for patients whose plan denies Wegovy or who cannot pass the prior-auth.
• Plan-specific PA churn. Many commercial plans require updated prior authorization at the start of a new plan year, after a formulary change, or after a medication switch. A switch from Zepbound to Foundayo (or vice versa) is typically a new PA, even within the same payer. Documentation requirements vary — most plans want BMI, comorbidities, prior trials, weight-loss outcomes from the prior agent, and a clinical justification for the switch.

The right place to start a payer conversation is your state insurance coverage page and the appeal playbook — both are anchored to verified state Medicaid policies and commercial plan publications.

Bottom line

Foundayo and Zepbound are different molecules with different routes (oral once-daily pill vs subcutaneous once-weekly injection), different dosing intervals, different approved strength tables, and different efficacy ceilings in the published phase 3 data (Foundayo 17.2 mg = −11.1% at 72 weeks in ATTAIN-1; Zepbound 15 mg = −20.9% at 72 weeks in SURMOUNT-1, separate trials, separate populations). The FDA labels for both drugs do NOT contain a dose-equivalence conversion table, and there is no published head-to-head trial comparing them as of mid-2026. The most defensible switching framework is to treat any cross-drug switch as functionally equivalent to a long missed-dose interval and apply each drug's own §2 missed-dose rule — in practice, restart at a low dose and re-titrate per the receiving drug's label. Patients of reproductive potential face a label-asymmetry on oral contraceptives (Zepbound has a bioavailability footnote; Foundayo does not). Insurance / formulary swaps drive most current switch questions. None of this constitutes medical advice — switching between Foundayo and Zepbound is a prescriber-level decision anchored to the individual patient. This article is the FDA-label evidence base; your prescriber is the decision-maker.

Related research

• Switching between GLP-1 medications (whole-class guide)
• Wegovy ↔ Zepbound switch dose-equivalence guide (Caremark-driven, SURMOUNT-5-anchored)
• Foundayo vs Wegovy vs Zepbound full comparison
• Foundayo week-by-week titration guide (Days 1-90)
• How to take Foundayo (general patient guide)
• Mounjaro / Zepbound birth-control warning evidence
• Insurance dropped coverage appeal playbook
• GLP-1 missed-dose decision guide (whole class)
• Orforglipron / Foundayo side effects
• Foundayo drug page
• Zepbound drug page
• GLP-1 medications pillar (every approved + investigational agent)